scholarly journals Long-term follow-up after mitral valve replacement in childhood: poor event-free survival in the young child☆

2007 ◽  
Vol 31 (5) ◽  
pp. 860-865 ◽  
Author(s):  
Wolfram Beierlein ◽  
Vera Becker ◽  
Robert Yates ◽  
Victor Tsang ◽  
Martin Elliott ◽  
...  
Heart ◽  
1972 ◽  
Vol 34 (2) ◽  
pp. 129-133 ◽  
Author(s):  
R S Barclay ◽  
J M Reid ◽  
J G Stevenson ◽  
T M Welsh ◽  
N McSwan

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
A Fuchs ◽  
B Iung ◽  
C Nguyen ◽  
J.L Carrasco ◽  
C Cimadevilla ◽  
...  

Abstract Background The growing use of surgical bioprostheses raises concerns about a future reoperation for bioprosthesis degeneration. There are few data on outcome after transcatheter mitral valve-in-valve implantation (TMVI) compared with redo surgical mitral valve replacement (SMVR). Purpose To compare the feasibility, safety and outcomes of TMVI versus SMVR for degenerated mitral bioprosthesis in high-risk patients. Methods In our institution, 52 patients underwent TMVI by transseptal approach and 33 SMVR for degenerated mitral bioprosthesis. The composite endpoint of event-free survival included cardiovascular mortality, stroke, major bleeding, hospitalization for heart failure or mitral valve reintervention. Results Mean age and EuroSCORE II were higher in TMVI group vs. SMVR group (age 63±21 years vs. 51±15 years, p=0.002; EuroSCORE II 12.5±12.2% vs. 6.2±3.3%, p=0.001) (Table). In-hospital mortality was 3.8% after TMVI vs. 3.0% after SMVR (p=1.0). Median follow-up was 2.2 years. At 5 years, survival was 69.7±9.4% after TMVI vs. 86.6±7.6% after SMVR (p=0.10) and event-free survival was lower after TMVI (40.1±9.9% vs 78.7±8.8% respectively, p=0.003) (Figure). In multivariate analysis, older age (p=0.02), neurologic history (p=0.05) and non-elective procedure (p<0.0001) were associated with lower event-free survival, while TMVI vs. SMVR was no longer significant (p=0.17). At last follow-up, 84% patients from TMVI group and 78% from SMVR group were NYHA I-II class. Mean mitral valve gradient and pulmonary artery systolic pressure were respectively 6.8±2.5 mmHg and 45±14 mmHg in TMVI group, and 4.8±2.0 mmHg and 37±11 mmHg in SMVR group. Conclusion TMVI is an alternative to SMVR in high-risk patients with degenerated mitral bioprosthesis. Comparison of mid-term results of the two techniques must take into account the differences in patient characteristics. Event-free survival Funding Acknowledgement Type of funding source: None


2018 ◽  
Vol 28 (5) ◽  
pp. 828-829
Author(s):  
Anne Moreau de Bellaing ◽  
Amel Mathiron ◽  
Yves Lecompte ◽  
Pascal Vouhé

2017 ◽  
Vol 65 (S 01) ◽  
pp. S1-S110
Author(s):  
M. Wilbring ◽  
E. Voigt ◽  
K. Alexiou ◽  
U. Kappert ◽  
S.M. Tugtekin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document